rs397509328
Variant summary
Our verdict is Benign. The variant received -11 ACMG points: 0P and 11B. BP4_ModerateBP6_Very_StrongBP7
The NM_007294.4(BRCA1):c.825C>T(p.Gly275Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000453 in 1,612,298 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★★).
Frequency
Consequence
NM_007294.4 synonymous
Scores
Clinical Significance
Conservation
Publications
- breast-ovarian cancer, familial, susceptibility to, 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- Fanconi anemia, complementation group SInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 4Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -11 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 151940Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000598 AC: 15AN: 250772 AF XY: 0.0000517 show subpopulations
GnomAD4 exome AF: 0.0000473 AC: 69AN: 1460240Hom.: 0 Cov.: 34 AF XY: 0.0000496 AC XY: 36AN XY: 726154 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152058Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74314 show subpopulations
ClinVar
Submissions by phenotype
not provided Benign:3
- -
- -
This variant is associated with the following publications: (PMID: 22615956, 20104584, 19370767, 16267036, 29168416) -
not specified Benign:2
- -
- -
Breast-ovarian cancer, familial, susceptibility to, 1 Benign:2
Synonymous substitution variant, with low bioinformatic likelihood to result in a splicing aberration (Splicing prior probability 0.02; http://priors.hci.utah.edu/PRIORS/). -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
Hereditary cancer-predisposing syndrome Benign:2
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
Malignant tumor of breast Benign:1
The BRCA1 p.Gly275= variant was identified in 3 of 115522 proband chromosomes (frequency: 0.00003) from individuals or families with breast cancer and was not identified in 278 control chromosomes from healthy individuals (Borg 2010, Judkins 2005, van der Stoep 2009). The variant was also identified in dbSNP (ID: rs397509328) as with uncertain significance allele. In addition, the variant was identified in the ClinVar and Clinvitae databases (as likely benign by Evidence-based Network for the Interpretation of Germline Mutant Alleles, Invitae, GeneDx and Ambry Genetics; and as uncertain significance by Integrated Genetics/Laboratory Corporation of America). The variant was further identified in the LOVD 3.0 database 8x with unknown effect; in the UMD-LSDB database (1x as uncertain significance variant). The variant was not identified in the COGR, Cosmic, MutDB, BIC, ARUP Laboratories, or Zhejiang University databases. The variant was identified in control databases in 15 of 245538 chromosomes at a frequency of 0.00006 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European Non-Finnish in 11 of 111318 chromosomes (freq: 0.0001), and East Asian in 4 of 17242 chromosomes (freq: 0.0002), while the variant was not observed in the African, Other, Latino, Ashkenazi Jewish, European Finnish, and South Asian populations. The variant was also identified in the 1000 Genomes Project in 2 of 5000 chromosomes (frequency: 0.0004). In order to study the effects of synonymous substitutions on BRCA1 splicing, RT-PCR of a mini-gene product was performed. The resulting BRCA1 splicing products showed that c.825C>T variant increases levels of an alternate BRCA1 splice variant referred to as D(11q) isoform, however the role of this isoform is unclear (Raponi 2012). The p.Gly275= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. -
BRCA1-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Hereditary breast ovarian cancer syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at